We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Nectin-4

News List

Competitive Landscape of the New Drug Target Nectin-4 in China Yefenghong/PharmaSources
May 22, 2023
Araris Biotech AG announced on April 17 that it will acquire ARS Pharmaceutical's Nectin-4 antibody. Araris Biotech intends to use the acquired Nectin-4 antibody to develop differentiated Nectin-4 ADCs using its proprietary linker technology.
A New Target in ADC: Nectin-4 PharmaSources/Yefenghong
September 14, 2021
Recently, the application for clinical trail of Mabwell's ADC drug (9MW2821) targeting Nectin-4 has been accepted by NMPA. It is the first time that domestic enterprise enters the IND stage with the same target drug.
Emergence Therapeutics Closes €87 Million Series A Financing Round contractpharma
December 08, 2021
Plans to advance its Nectin-4 antibody drug conjugate.
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle Toxin Conjugate BT8009 in Patients with Advanced Solid Tumors Business Wire
September 24, 2020
Bicycle Therapeutics plc today announced the first patient has been dosed in the Phase I dose escalation portion of a company-sponsored Phase I/II trial of BT8009.